#USA #Hamilton #radiopharmaceuticals #AtomVie #Jubilant

Strengthening the Radiopharmaceutical Supply Chain

On October 15, 2026, AtomVie Global Radiopharma, a leading contract development and manufacturing organization (CDMO) in the radiopharmaceutical sector, announced a strategic partnership with Jubilant Radiopharma. This collaboration aims to enhance logistics, regulatory compliance, and last-mile distribution services specifically for clinical trials.

Key Objectives of the Partnership
The alliance seeks to provide comprehensive support for AtomVie’s growing portfolio of radiopharmaceutical programs. Jubilant Radiopharma will manage key aspects such as the acceptance, processing, and regulatory adherence related to the distribution of radiopharmaceuticals through its expansive pharmacy network across the United States. This initiative is set to optimize delivery to clinical sites while maintaining the high standards of quality and safety necessary for these specialized products.

Bruno Paquin, CEO of AtomVie, emphasized the importance of robust logistics and distribution capabilities in the ever-expanding radiopharmaceutical field. He stated, "With continued growth in the radiopharmaceutical sector, it is imperative to establish strong logistical and distribution capabilities to ensure that patients and clinical sites receive products reliably and efficiently." He highlighted Jubilant Radiopharma's extensive pharmacy network and regulatory expertise as ideal for advancing AtomVie’s clinical development support.

Commitment to Patient Accessibility
Harsher Singh, CEO of Jubilant Radiopharma, echoed this sentiment, affirming the company's commitment to ensuring safe, compliant, and dependable delivery of radiopharmaceutical therapies across North America. He acknowledged their role as a trusted partner for therapeutic clinical trials and market introduction. "Our collaboration with AtomVie reflects our shared commitment to accelerating innovation and expanding patient access to the next generation of radiopharmaceutical therapies," Singh noted.

Integration of Services
The partnership is expected to significantly bolster AtomVie’s integrated service offerings. By leveraging Jubilant Radiopharma's established distribution infrastructure and specialized knowledge in clinical trials and therapeutic delivery, both companies will enhance operational flexibility and improve access to clinical study sites.

About AtomVie Global Radiopharma

AtomVie Global Radiopharma Inc. is internationally recognized for its commitment to the development and production of radiopharmaceuticals. The company offers integrated solutions that encompass process development, GMP-compliant manufacturing, quality control, regulatory support, and global distribution services for clinical and commercial programs. Operating from a state-of-the-art facility in Hamilton, Ontario, AtomVie collaborates with pharmaceutical and biotechnology companies worldwide to develop innovative radiotherapeutics and diagnostics.

About Jubilant Radiopharma

Jubilant Radiopharma, a division of Jubilant Pharmova Limited, stands as a prominent player in the radiopharmaceutical industry. With a focus on developing, manufacturing, distributing, and marketing radiopharmaceutical products, Jubilant supports diagnostic and therapeutic programs with extensive logistics for clinical trials, regulatory support, therapeutic delivery, site activation, and nationwide distribution capabilities. With over 70 years of experience in nuclear medicine, Jubilant Radiopharma aims to improve patient access and drive innovation across the field. Their motto is clear: "Enhancing Quality of Life through Nuclear Medicine."

In conclusion, the partnership between AtomVie and Jubilant Radiopharma signifies a strategic move that promises to enhance the logistics and distribution network necessary for advancing clinical trials and ensuring that patients benefit from innovative therapies. This collaboration is poised to shape the future of radiopharmaceuticals, ensuring efficient delivery to those who need it most.